Women who’ve been treated for hormone-sensitive breast cancer often face five to 10 years of endocrine therapy to lower the chances of their tumors coming back. Because that drug regimen is toxic ...
A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more ...
The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...
Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating how the Breast Cancer Index® ...
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...
Please provide your email address to receive an email when new articles are posted on . “Endocrine therapy is the mainstay of treatment for patients with localized and metastatic ...
Roche (RHHBF) stock is in focus as the FDA grants priority review for breast cancer therapy giredestrant with a target action ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results